Roche signs inclacumab deal with GBT
Roche has sold off rights to inclacumab to Global Blood Therapeutics, which intends to develop the treatment for vaso-occlusive crises (VOC) in patients with sickle cell disease (SCD).
Read More
Tag: VOC
GSK to use Owlstone’s breath biopsy in COPD trial
In a major boon for UK diagnostics group Owlstone Medical, GlaxoSmithKline is incorporating the firm’s Breath Biopsy platform into the clinical development programme for its novel, experimental respiratory drug danirixin.
Read More
UK launch for world’s largest breath-based study into bowel cancer
UK diagnostics group Owlstone Medical has kicked off a 1,400 patient clinical trial assessing the potential of its FAIMS (Field Asymmetric Ion Mobility Spectrometer) technology in the early detection of colorectal cancer, which it claims to be the world’s largest breath-based study into the disease.
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
